Systematic Reviews
Copyright ©The Author(s) 2016.
World J Hepatol. Nov 28, 2016; 8(33): 1478-1488
Published online Nov 28, 2016. doi: 10.4254/wjh.v8.i33.1478
Table 1 The information of top 100 cited articles in nonalcoholic fatty liver disease
RankTitle of articleJournalFirst author/instituteYearTimes cited
1Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatologyKleiner DE/NCI, United States20052151
2Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesionsAm J GastroenterolBrunt EM/Saint Louis University, United States19991609
3Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severityGastroenterologyMatteoni CA/Cleveland Clin Fdn, United States19991506
4Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicityHepatologyBrowning JD/Univ Texas, United States20041320
5Non-alcoholic steatohepatitis - Mayo-Clinic experiences with A hitherto unnamed diseaseMayo Clin ProcLudwig J/Mayo Clin, United States19801206
6Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatologyMarchesini G/Università di Bologna, Bologna, Italy20031134
7Nonalcoholic fatty liver disease - a feature of the metabolic syndromeDiabetesMarchesini G/Univ Bologna, Italy20011072
8The natural history of nonalcoholic fatty liver disease: A population-based cohort studyGastroenterologyAdams LA/Mayo Clin, United States2005974
9Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalitiesGastroenterologySanyal AJ/Virginia Commonwealth Univ, United States2001935
10The natural-history of nonalcoholic steatohepatitis - a follow-up-study of 42 patients for up to 21 yrHepatologyPowell EE/University of Queensland, Australia1990864
11Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitisHepatologyAngulo P/Mayo Clin, United States1999802
12Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver diseaseJ Clin InvestDonnelly KL/Univ Minnesota, United States2005801
13Nonalcoholic steatohepatitis - an expanded clinical entityGastroenterologyBacon BR/St. Louis UNIV, United States1994756
14Association of nonalcoholic fatty liver disease with insulin resistanceAm J MedMarchesini G/Univ Bologna, United States1999736
15Long-term follow-up of patients with NAFLD and elevated liver enzymesHepatologyEkstedt M/Linkoping Univ Hosp, Sweden2006719
16Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinomaGastroenterologyBugianesi E/Univ Turin, Italy2002712
17The utility of radiological imaging in nonalcoholic fatty liver diseaseGastroenterologySaadeh S/Inova Fairfax Hosp, United States2002708
18The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in miceJ Clin InvestXu AM/Univ Auckland, China2003696
19Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obeseGastroenterologyDixon JB/Monash Univ, Australia2001666
20A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitisN Engl J MedBelfort R/Univ Texas, Italy2006662
21Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature GenetRomeo S/Univ Texas, United States2008614
22NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndromeHepatologyChitturi S/Univ Sydney, Australia2002610
23Sampling variability of liver biopsy in nonalcoholic fatty liver diseaseGastroenterologyRatziu V/Grp Hosp Pitie Salpetriere, France2005572
24Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal menJ Clin Endocrinol MetabSeppala-Lindroos A/Univ Helsinki, Finland2002563
25Beyond insulin resistance in NASH: TNF-alpha or adiponectin?HepatologyHui JM/Westmead Hosp, Australia2004552
26Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general populationAm J Physiol -Endocrinol MetabSzczepaniak, LS/Univ Texas, United States2005551
27Pioglitazone, Vitamin E or Placebo for Nonalcoholic SteatohepatitisN Engl J MedSanyal AJ/Virginia Commonwealth Univ, United States2010550
28The natural history of nonalcoholic fatty liver: A follow-up studyHepatologyTeli MR/Univ Newcastle, United Kingdom1995544
29Mechanism of hepatic insulin resistance in non-alcoholic fatty liver diseaseJ. Biol. Chem.Samuel VT/Yale Univ, Australia2004537
30Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitisProc Natl Acad Sci USAYang SQ/Johns Hopkins Univ, United States1997504
31Prevalence of fatty liver in children and adolescentsPediatricsSchwimmer JB/Univ Calif San Diego, United States2006454
32Diabetes increases the risk of chronic liver disease and hepatocellular carcinomaGastroenterologyEl-Serag HB/Houston Dept Vet Affairs Med Ctr, United States2004452
33Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitisGastroenterologyFeldstein AE/Mayo Clin, United States2003451
34Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver StudyHepatologyBedogni G/Fondo Studio Malattie Fegato ONLUS, Italy2005449
35CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitisJ Clin InvestLeclercq IA/Univ Sydney, United States2000435
36Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver diseaseHepatologyLi ZP/Johns Hopkins Univ, United States2003433
37Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosisGastroenterologyGeorge DK/Royal Brisbane Hosp, Australia1998431
38Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT valuesHepatologyMofrad P/Virginia Commonwealth Univ, U United States2003427
39The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDHepatologyAngulo P/Mayo Clin, United Kingdom2007425
40A pilot study of ploglitazone treatment for nonalcoholic steatohepatitisHepatologyPromrat K/NIDDK, United States2004410
41Improved nonalcoholic steatohepatitis after 48 wk of treatment with the PPAR-gamma ligand rosiglitazoneHepatologyNeuschwander-Tetri BA/St. Louis Univ, United States2003406
42Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityNatureHenao-Mejia J/Yale Univ, United States2012399
43Liver pathology and the metabolic syndrome X in severe obesityJ Clin Endocrinol MetabMarceau P/SUNY Hlth Sci Ctr, Canada1999389
44The metabolic syndrome as a predictor of nonalcoholic fatty liver diseaseAnn Intern MedHamaguchi M/Asahi Univ, Japan2005387
45Metformin in non-alcoholic steatohepatitisLancetMarchesini G/Univ Bologna, Italy2001376
46Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic associationHepatologyPagano G/Univ Turin, Italy2002373
47Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant miceProc Natl Acad Sci USADumas ME/Univ London Imperial Coll Sci Technol & Med, United Kingdom2006361
48Hepatic cytochrome p450 2E1 is increased in patients with nonalcoholic steatohepatitisHepatologyWeltman MD/Westmead Hosp, Sweden1998355
49The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsiesJ HepatolAdams LA/Mayo Clin, United States2005349
50Nonalcoholic steatohepatitis - A study of 49 patientsHum PatholLee RG/Oregon Health Sciences University, United States1989346
51Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective StudyGastroenterologyWilliams CD/Brooke Army Med Ctr, United States2011343
52Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathwayHepatologyFeldstein AE/Mayo Clin, United States2004336
53In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver diseaseHepatologyWieckowska A/Cleveland Clin Fdn, United States2006330
54Therapeutic effects of restricted diet and exercise in obese patients with fatty liverJ HepatolUeno T/Kurume University School of Medicine, Japan1997329
55Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patientsHepatologyCrespo J/Hosp Univ Marques Valdecilla, Spain2001327
56Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitisHepatologyYamaguchi K/Duke Univ, United States2007324
57Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight lossHepatologyDixon JB/Monash Univ, Australia2004324
58The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitisGutWigg AJ/Queen Elizabeth Hosp, Australia2001324
59Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesityProc Natl Acad Sci USAFabbrini E/Washington Univ, Greece2009323
60Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot studyHepatologyLaurin J/Mayo Clin, United States1996317
61Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot studyJ PediatrLavine JE/Univ Calif San Diego, United States2000312
62A randomized controlled trial of metformin vs vitamin E or prescriptive diet in nonalcoholic fatty liver diseaseAm J GastroenterolBugianesi E/Univ Bologna, Italy2005309
63Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trialHepatologyLindor KD/Mayo Clin, Canada2004305
64Deletion of NEMO/IKK gamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinomaCancer CellLuedde T/Univ Cologne, Belgium2007285
65NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United StatesHepatologyMarrero JA/Univ Michigan, United States2002283
66Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitisAm J GastroenterolHarrison SA/Univ Texas, United States2003281
67High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitisHepatologyParadis V/Hop Bicetre, France2001281
68Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control studyHepatologyPoonawala A/Johns Hopkins Univ, United States2000281
69Insulin resistance-associated hepatic iron overloadGastroenterologyMendler MH/Hop Pontchaillou, France1999281
70Free fatty acids induce JNK-dependent hepatocyte lipoapoptosisJ Biol ChemMalhi H/Mayo Clin, United States2006280
71Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitisHepatologyMusso G/Univ Turin, Italy2003279
72Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin EHepatologyKugelmas M/Univ Louisville, United States2003275
73Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patientsDiabetesTargher G/Osped Sacro Cuore don G Calabria, Italy2005271
74A lipidomic analysis of nonalcoholic fatty liver diseaseHepatologyPuri P/Virginia Commonwealth Univ, United States2007269
75The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic SteatohepatitisHepatologyAscha MS/Cleveland Clin, United States2010268
76Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patientsDiabetes CareTargher G/Osped Sacro Cuore don Calabria, United Kingdom2007268
77Burden of liver disease in the United States: Summary of a workshopHepatologyKim WR/Mayo Clin, United States2002266
78Plasma Endotoxin Concentrations In Patients With Alcoholic And Nonalcoholic Liver-Disease - Reevaluation With An Improved Chromogenic AssayJ HepatolFukui H/ROBERT BOSCH KRANKENHAUS, Germany1991264
79Histopathology of pediatric nonalcoholic fatty liver diseaseHepatologySchwinnner JB/Univ Calif San Diego, USA2005262
80A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJ HepatolRatziu V/Azienda USL Modena, Italy2010259
81Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitisAm J Physiol-Gastroint Liver PhysiolBrun P/Univ Padua, Italy2007258
82Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver diseaseHepatologyVillanova N/Alma Mater Studiorum Univ Bologna, Italy2005258
83Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitisHepatologyPerez-Carreras M/Hosp Univ 12 Octubre, Spain2003254
84Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosisHepatologyRatziu V/Hop La Pitie Salpetriere, France2002254
85A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitisAm J GastroenterolCaldwell SH/Univ Virginia, United States2001247
86Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomasJ Clin InvestHorie Y/Akita Univ, Japan2004240
87Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatologyPromrat K/Brown Univ, United States2010239
88Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosisGastroenterologyMoucari R/Hop Beaujon, France2008239
89Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot studyAm J GastroenterolAbdelmalek MF/Mayo Clin, United States2001239
90Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcoholHepatologyMonto A/Univ Calif San Francisco, United States2002237
91Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitisHepatologyYokohama S/Dokkyo Univ, Japan2004235
92Hepatic-Effects Of Dietary Weight-Loss In Morbidly Obese SubjectsJ HepatolAndersen T/Univ Copenhagen, Denmark1991236
93Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy trialGastroenterologyRatziu V/Univ Paris, France2008234
94Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver DiseaseHepatologyWong VWS/Hop Haut Leveque, China2010232
95Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammationGastroenterologyWeltman MD/Univ Sydney, Australia1996230
96Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastasesJ Am Coll SurgFernandez FG/Washington Univ, United States2005229
97Adiponectin and its receptors in non-alcoholic steatohepatitisGutKaser S/Univ Innsbruck Hosp, Spain2005229
98Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis CHepatologyHui JM/Univ Sydney, Australia2003229
99Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markersHepatologyGuha IN/Guha, United Kingdom2008228
100Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severityJ Clin Endocrinol MetabBugianesi E/Univ Turin, Italy2005227
Table 2 Countries of origin of the top 100 articles in nonalcoholic fatty liver disease
1United States554845104926975
5United Kingdom752521826
16New Zealand100110
18South Africa100100
Table 3 Top productive institutions list with top 100 cited articles in nonalcoholic fatty liver disease
1Mayo Clinic121284115950
2University of Bologna951853627
2University of Turin941841591
4The University of Sydney741621504
5University of California, San Diego630631028
6University of Texas551443428
7Saint Louis University533232771
8Virginia Commonwealth University542322181
9Westmead Hospital42043907
10Washington University42041552
11University of Paris41041234
12University of California, San Francisco41130237
13National Cancer Institute410412151
14MetroHealth Medical Center400400
Table 4 Most frequent subspecialties with the top 100 cited articles in nonalcoholic fatty liver disease
RankSubject categoriesNo. of articlesTotal citation
1Gastroenterology and Hepatology7133290
2Endocrinology and Metabolism73341
3General and Internal Medicine63917
4Research and Experimental Medicine42172
5Science and Technology41587
6Biochemistry and Molecular Biology2817
9Genetics and Heredity1614
11Cell Biology1285
Table 5 Journal distribution of top 100 cited articles in nonalcoholic fatty liver disease
RankJournalNo. of articlesTotal citationImpact factor (2014)
3Am J Gastroenterol5268510.755
3J Hepatol5143711.336
5J Clin Invest4217213.215
6Proc Natl Acad Sci USA311889.674
7J Clin Endocrinol Metab311793.457
9New Engl J Med2121255.873
10J Biol Chem28174.573
Table 6 High frequency key words in the top 100 cited articles in nonalcoholic fatty liver disease (frequency > 2)
RankKey wordFrequency
1Hepatic steatosis4
4Metabolic syndrome2
4Insulin resistance2
4Intestinal bacteria2
Table 7 Highly related concepts of the top 100 articles in nonalcoholic fatty liver disease categorized by GoPubMed® search engine
RankHighly related conceptsFrequencyRankHighly related conceptsFrequency
1Fatty liver9724Wounds and injuries15
2Male9125Aspartate Aminotransferases14
4Female8427Carcinoma, Hepatocellular13
5Middle aged7228Tumor necrosis factor-alpha12
6Patients7129Multivariate analysis12
7Fibrosis5930Prospective studies12
8Biopsy4531Follow-up studies12
9Liver4532Hepatitis C11
10Obesity4233cell killing11
13Serum3236Metabolic syndrome X10
14Body mass index3137Fatty acids, nonesterified10
15Syndrome2538Aspartic acid10
16Risk Factors2439Hypoglycemic agents10
17Alanine transaminase2340Homeostasis10
18Alanine transaminase activity1941Severity of illness index10
20Prevalence1843Personal autonomy10